Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for BBIO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 -148.77M
March 31, 2026 549.89M
December 31, 2025 -2.782M
September 30, 2025 -0.894M
June 30, 2025 300.49M
March 31, 2025 60.33M
December 31, 2024 473.93M
September 30, 2024 0.707M
June 30, 2024 -5.729M
March 31, 2024 279.55M
December 31, 2023 -4.523M
September 30, 2023 307.04M
June 30, 2023 -1.231M
March 31, 2023 150.25M
December 31, 2022 5.257M
September 30, 2022 1.445M
June 30, 2022 -20.80M
Date Value
March 31, 2022 0.96M
December 31, 2021 325.38M
September 30, 2021 -138.64M
June 30, 2021 83.38M
March 31, 2021 547.91M
December 31, 2020 9.531M
September 30, 2020 1.782M
June 30, 2020 0.703M
March 31, 2020 414.08M
December 31, 2019 3.823M
September 30, 2019 168.84M
June 30, 2019 20.22M
March 31, 2019 -0.715M
December 31, 2018 318.37M
September 30, 2018 -1.744M
June 30, 2018 167.19M
March 31, 2018 3.501M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 36.24M
Ionis Pharmaceuticals, Inc. -412.29M
Pfizer Inc. -3.663B
Vertex Pharmaceuticals, Inc. -426.70M
BioMarin Pharmaceutical, Inc. 2.738B